These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 10369798)

  • 1. Effects of treatment of rheumatoid arthritis patients with an antibody against tumour necrosis factor alpha on reticuloendothelial and intrapulmonary granulocyte traffic.
    Taylor PC; Peters AM; Glass DM; Maini RN
    Clin Sci (Lond); 1999 Jul; 97(1):85-9. PubMed ID: 10369798
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early effects of tumour necrosis factor alpha blockade on skin and synovial tissue in patients with active psoriasis and psoriatic arthritis.
    Goedkoop AY; Kraan MC; Teunissen MB; Picavet DI; de Rie MA; Bos JD; Tak PP
    Ann Rheum Dis; 2004 Jul; 63(7):769-73. PubMed ID: 15194570
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment with monoclonal anti-tumor necrosis factor alpha antibody results in an accumulation of Th1 CD4+ T cells in the peripheral blood of patients with rheumatoid arthritis.
    Maurice MM; van der Graaff WL; Leow A; Breedveld FC; van Lier RA; Verweij CL
    Arthritis Rheum; 1999 Oct; 42(10):2166-73. PubMed ID: 10524689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravascular tumor necrosis factor alpha blockade reverses endothelial dysfunction in rheumatoid arthritis.
    Cardillo C; Schinzari F; Mores N; Mettimano M; Melina D; Zoli A; Ferraccioli G
    Clin Pharmacol Ther; 2006 Sep; 80(3):275-81. PubMed ID: 16952494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between the level of circulating bioactive tumor necrosis factor alpha and the tumor necrosis factor alpha gene polymorphism at -308 in patients with rheumatoid arthritis treated with a tumor necrosis factor alpha inhibitor.
    Marotte H; Arnaud B; Diasparra J; Zrioual S; Miossec P
    Arthritis Rheum; 2008 May; 58(5):1258-63. PubMed ID: 18438841
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor necrosis factor alpha blockade treatment down-modulates the increased systemic and local expression of Toll-like receptor 2 and Toll-like receptor 4 in spondylarthropathy.
    De Rycke L; Vandooren B; Kruithof E; De Keyser F; Veys EM; Baeten D
    Arthritis Rheum; 2005 Jul; 52(7):2146-58. PubMed ID: 15986373
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Macrophages expressing the scavenger receptor CD163: a link between immune alterations of the gut and synovial inflammation in spondyloarthropathy.
    Baeten D; Demetter P; Cuvelier CA; Kruithof E; Van Damme N; De Vos M; Veys EM; De Keyser F
    J Pathol; 2002 Mar; 196(3):343-50. PubMed ID: 11857499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparative study into the mechanisms of action of anti-tumor necrosis factor alpha, anti-CD4, and combined anti-tumor necrosis factor alpha/anti-CD4 treatment in early collagen-induced arthritis.
    Marinova-Mutafchieva L; Williams RO; Mauri C; Mason LJ; Walmsley MJ; Taylor PC; Feldmann M; Maini RN
    Arthritis Rheum; 2000 Mar; 43(3):638-44. PubMed ID: 10728758
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab.
    Bendtzen K; Geborek P; Svenson M; Larsson L; Kapetanovic MC; Saxne T
    Arthritis Rheum; 2006 Dec; 54(12):3782-9. PubMed ID: 17133559
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumour necrosis factor alpha (TNF-alpha) interferes with Fas-mediated apoptotic cell death on rheumatoid arthritis (RA) synovial cells: a possible mechanism of rheumatoid synovial hyperplasia and a clinical benefit of anti-TNF-alpha therapy for RA.
    Ohshima S; Mima T; Sasai M; Nishioka K; Shimizu M; Murata N; Yoshikawa H; Nakanishi K; Suemura M; McCloskey RV; Kishimoto T; Saeki Y
    Cytokine; 2000 Mar; 12(3):281-8. PubMed ID: 10704256
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Surface-bound anti-type II collagen-containing immune complexes induce production of tumor necrosis factor alpha, interleukin-1beta, and interleukin-8 from peripheral blood monocytes via Fc gamma receptor IIA: a potential pathophysiologic mechanism for humoral anti-type II collagen immunity in arthritis.
    Mullazehi M; Mathsson L; Lampa J; Rönnelid J
    Arthritis Rheum; 2006 Jun; 54(6):1759-71. PubMed ID: 16736518
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo blockade of tumor necrosis factor-alpha in patients with rheumatoid arthritis: longterm effects after repeated infusion of chimeric monoclonal antibody cA2.
    Lorenz HM; Grünke M; Hieronymus T; Antoni C; Nüsslein H; Schaible TF; Manger B; Kalden JR
    J Rheumatol; 2000 Feb; 27(2):304-10. PubMed ID: 10685789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blockade of tumour necrosis factor-alpha in rheumatoid arthritis: effects on components of rheumatoid cachexia.
    Metsios GS; Stavropoulos-Kalinoglou A; Douglas KM; Koutedakis Y; Nevill AM; Panoulas VF; Kita M; Kitas GD
    Rheumatology (Oxford); 2007 Dec; 46(12):1824-7. PubMed ID: 18032540
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pulmonary granulocyte kinetics in relation to endothelial and granulocyte activation.
    Ussov WY; Peters AM; Chapman PT; Ttofi A; Mason JC; Haskard DO; Hughes JM
    Clin Sci (Lond); 1999 May; 96(5):525-31. PubMed ID: 10209085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytokine and chemokine receptor profile of peripheral blood mononuclear cells during treatment with infliximab in patients with active rheumatoid arthritis.
    Nissinen R; Leirisalo-Repo M; Peltomaa R; Palosuo T; Vaarala O
    Ann Rheum Dis; 2004 Jun; 63(6):681-7. PubMed ID: 15140775
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune complexes from rheumatoid arthritis synovial fluid induce FcgammaRIIa dependent and rheumatoid factor correlated production of tumour necrosis factor-alpha by peripheral blood mononuclear cells.
    Mathsson L; Lampa J; Mullazehi M; Rönnelid J
    Arthritis Res Ther; 2006; 8(3):R64. PubMed ID: 16569263
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stress activation of cellular markers of inflammation in rheumatoid arthritis: protective effects of tumor necrosis factor alpha antagonists.
    Motivala SJ; Khanna D; FitzGerald J; Irwin MR
    Arthritis Rheum; 2008 Feb; 58(2):376-83. PubMed ID: 18240230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of variants of Fc gamma receptors IIA and IIIA on the American College of Rheumatology and European League Against Rheumatism responses to anti-tumour necrosis factor alpha therapy in rheumatoid arthritis.
    Cañete JD; Suárez B; Hernández MV; Sanmartí R; Rego I; Celis R; Moll C; Pinto JA; Blanco FJ; Lozano F
    Ann Rheum Dis; 2009 Oct; 68(10):1547-52. PubMed ID: 18930989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Responsiveness to anti-tumour necrosis factor alpha therapy is related to pre-treatment tissue inflammation levels in rheumatoid arthritis patients.
    van der Pouw Kraan TC; Wijbrandts CA; van Baarsen LG; Rustenburg F; Baggen JM; Verweij CL; Tak PP
    Ann Rheum Dis; 2008 Apr; 67(4):563-6. PubMed ID: 18042642
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased DHEAS levels in patients with rheumatoid arthritis after treatment with tumor necrosis factor antagonists: evidence for improved adrenal function.
    Ernestam S; Hafström I; Werner S; Carlström K; Tengstrand B
    J Rheumatol; 2007 Jul; 34(7):1451-8. PubMed ID: 17477470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.